Resistance to taxanes is induced by c-erbB-2 overexpression in human MCF-10A mammary epithelial cells and is blocked by combined treatment with an antisense oligonucleotide targeting type I protein kinase AF Ciardiello
Cattedra di Oncologia Medica, Dipartimento di Endocrinologia e Oncologia Molecolare e Clinica, Facolta di Medicina e Chirurgia, Universita degli Studi di Napoli Federico II, Naples, Italy
Int J Cancer 85:710-5. 2000
....
- Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy
Fortunato Ciardiello
Cattedra di Oncologia Medica, Dipartimento Medico Chirurgico di Internistica Clinica e Sperimentale F Magrassi e A Lanzara, Seconda Universita degli Studi di Napoli, Naples, Italy
Clin Cancer Res 10:784-93. 2004
..ZD6474 is a small molecule VEGF flk-1/KDR (VEGFR-2) tyrosine kinase inhibitor that also demonstrates inhibitory activity against EGFR tyrosine kinase...
- Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase
Fortunato Ciardiello
Cattedra di Oncologia Medica, Dipartimento di Endocrinologia e Oncologia Molecolare e Clinica, Universita degli Studi di Napoli Federico II, 5 80131 Naples, Italy
Clin Cancer Res 9:1546-56. 2003
..ZD6474 is a p.o. bioavailable, VEGF flk-1/KDR receptor (VEGFR-2) tyrosine kinase inhibitor with antitumor activity in many human cancer xenografts and is currently in Phase I clinical development...
- Anti-epidermal growth factor receptor drugs in cancer therapy
Fortunato Ciardiello
Cattedra di Oncologia Medica, Dipartimento di Endocrinologia e Oncologia Molecolare e Clinica, Universita di Napoli Federico II, Via S Pansini 5, 80131 Naples, Italy
Expert Opin Investig Drugs 11:755-68. 2002
..Results from Phase I - II trials in advanced cancer demonstrate that these drugs have an acceptable tolerability and an interesting clinical activity in patients with a variety of tumour types...
- ZD1839 (IRESSA), an EGFR-selective tyrosine kinase inhibitor, enhances taxane activity in bcl-2 overexpressing, multidrug-resistant MCF-7 ADR human breast cancer cells
Fortunato Ciardiello
Dipartimento di Endocrinologia e Oncologia Molecolare e Clinica, Universita di Napoli Federico II, Naples, Italy
Int J Cancer 98:463-9. 2002
..These results demonstrate the ability of ZD1839 to overcome taxane resistance in a model of hormone-independent, multidrug-resistant, human breast cancer...
- A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor
F Ciardiello
Cattedra di Oncologia Medica, Dipartimento di Endocrinologia e Oncologia Molecolare e Clinica, Universita di Napoli Federico II, Via S Pansini 5, 80131 Naples, Italy
Clin Cancer Res 7:2958-70. 2001
..This mini-review describes the EGFR inhibitors in clinical development...
- Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor
F Ciardiello
Cattedra di Oncologia Medica, Dipartimento di Endocrinologia e Oncologia Molecolare e Clinica, Universita degli Studi di Napoli Federico II, 80131 Naples, Italy
Clin Cancer Res 7:1459-65. 2001
....
- Epidermal growth factor receptor tyrosine kinase inhibitors as anticancer agents
F Ciardiello
Cattedra di Oncologia Medica, Dipartimento di Endocrinologia e Oncologia Molecolare e Clinica, Universita degli Studi di Napoli Federico II, Italy
Drugs 60:25-32; discussion 41-2. 2000
..Preclinical data for ZD1839 strongly support the possibility of potentiating the antitumour activity of conventional chemotherapy with agents that selectively block the EGFR...
- Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells
F Ciardiello
Cattedra di Oncologia Medica, Dipartimento di Endocrinologia e Oncologia Molecolare e Clinica, Facolta di Medicina e Chirurgia, Universita degli Studi di Napoli Federico II, Naples, Italy
Clin Cancer Res 6:3739-47. 2000
..Finally, a significant potentiation in inhibition of VEGF expression and little or no microvessels were observed in GEO tumors after the combined treatment with the two agents...
- Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor
F Ciardiello
Cattedra di Oncologia Medica, Dipartimento di Endocrinologia e Oncologia Molecolare e Clinica, Universita degli Studi di Napoli Federico II, Naples, Italy
Clin Cancer Res 6:2053-63. 2000
..These results demonstrate the antitumor effect of this EGFR-selective tyrosine kinase inhibitor and provide a rationale for its clinical evaluation in combination with cytotoxic drugs...
- Combined targeted inhibition of bcl-2, bcl-XL, epidermal growth factor receptor, and protein kinase A type I causes potent antitumor, apoptotic, and antiangiogenic activity
Giampaolo Tortora
Dipartimento di Endocrinologia e Oncologia Molecolare e Clinica, Universita di Napoli Federico II, 80131 Napoli, Italy
Clin Cancer Res 9:866-71. 2003
....
- Combined targeting of epidermal growth factor receptor and MDM2 by gefitinib and antisense MDM2 cooperatively inhibit hormone-independent prostate cancer
Roberto Bianco
Dipartimento di Endocrinologia e Oncologia Molecolare e Clinica, , Naples, Italy
Clin Cancer Res 10:4858-64. 2004
....
Synergistic antitumor activity of sorafenib in combination with epidermal growth factor receptor inhibitors in colorectal and lung cancer cellsErika Martinelli
Dipartimento Medico Chirurgico di Internistica Clinica e Sperimentale F Magrassi e A Lanzara, Seconda Universita degli Studi di Napoli, Napoli, Italy
Clin Cancer Res 16:4990-5001. 2010
..Cancer cell survival, invasion, and metastasis depend on cancer cell proliferation and on tumor-induced angiogenesis. We evaluated the efficacy of the combination of sorafenib and erlotinib or cetuximab...
- Novel toll-like receptor 9 agonist induces epidermal growth factor receptor (EGFR) inhibition and synergistic antitumor activity with EGFR inhibitors
Vincenzo Damiano
Dipartimento di Endocrinologia e Oncologia Molecolare e Clinica, Istituto di Anatomia Patologica, and Dipartimento di Biologia e Patologia Cellulare e Molecolare, , Via S. Pansini 5, 80131 Naples, Italy
Clin Cancer Res 12:577-83. 2006
..Moreover, this therapeutic strategy could be translated in patients affected by colorectal cancer...
- Cooperative antitumor effect of multitargeted kinase inhibitor ZD6474 and ionizing radiation in glioblastoma
Vincenzo Damiano
Cattedra di Oncologia Medica, Dipartimento di Endocrinologia e Oncologia Molecolare e Clinica, , Italy
Clin Cancer Res 11:5639-44. 2005
....
- Enhancement of antitumor activity of ionizing radiation by combined treatment with the selective epidermal growth factor receptor-tyrosine kinase inhibitor ZD1839 (Iressa)
Cataldo Bianco
Cattedra di Oncologia Medica, Dipartimento di Endocrinologia e Oncologia Molecolare e Clinica, , 80131 Naples, Italy
Clin Cancer Res 8:3250-8. 2002
..CONCLUSION: This study provides a rationale for evaluating in cancer patients the combination of ionizing radiation and selective EGFR tyrosine kinase inhibitors such as ZD1839...
- Combination of a selective cyclooxygenase-2 inhibitor with epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 and protein kinase A antisense causes cooperative antitumor and antiangiogenic effect
Giampaolo Tortora
Dipartimento di Endocrinologia e Oncologia Molecolare e Clinica, Universita di Napoli Federico II, 80131 Napoli, Italy
Clin Cancer Res 9:1566-72. 2003
..Therefore, we investigated whether any cooperative antitumor effect can be obtained by the combined blockade of COX-2, EGFR, and PKAI...
- Antitumor activity of ZD6474, a vascular endothelial growth factor-2 and epidermal growth factor receptor small molecule tyrosine kinase inhibitor, in combination with SC-236, a cyclooxygenase-2 inhibitor
Concetta Tuccillo
Dipartimento Medico-Chirurgico di Internistica Clinica e Sperimentale F Magrassi e A Lanzara, , Via S. Pansini 5, 80131 Naples, Italy
Clin Cancer Res 11:1268-76. 2005
..CONCLUSIONS: This study provides a rationale for evaluating the simultaneous blockade of EGFR, COX-2, and VEGF signaling as cancer therapy in a clinical setting...
- Vascular endothelial growth factor receptor-1 contributes to resistance to anti-epidermal growth factor receptor drugs in human cancer cells
Roberto Bianco
Cattedra di Oncologia Medica, Dipartimento di Endocrinologia e Oncologia Molecolare e Clinica, Universita di Napoli Federico II, Via S Pansini 5, Naples, Italy
Clin Cancer Res 14:5069-80. 2008
..Combined inhibition of EGFR and other signaling proteins has become a successful therapeutic approach, stimulating the search for further determinants of resistance as basis for novel therapeutic strategies...
- Zoledronic acid cooperates with a cyclooxygenase-2 inhibitor and gefitinib in inhibiting breast and prostate cancer
Davide Melisi
Cattedra di Oncologia Medica, Dipartimento di Endocrinologia e Oncologia Molecolare e Clinica, , Naples, Italy
Endocr Relat Cancer 12:1051-8. 2005
....
- Prognostic significance of epidermal growth factor receptor expression in colon cancer patients undergoing curative surgery
Gennaro Galizia
Division of Surgical Oncology, F Magrassi and A Lanzara Department of Clinical and Experimental Medicine and Surgery, Second University of Naples School of Medicine, Naples, 80131, Italy
Ann Surg Oncol 13:823-35. 2006
..To investigate the role of epidermal growth factor receptor (EGFR) expression as a prognostic marker for prediction of cancer behavior and clinical outcomes in colon cancer patients undergoing potentially curative surgery...
- Weekly chemotherapy with cisplatin and paclitaxel and concurrent radiation therapy as preoperative treatment in locally advanced esophageal cancer: a phase II study
Michele Orditura
Division of Medical Oncology, Department of Clinical and Experimental Medicine and Surgery F Magrassi e A Lanzara, Second University of Naples, School of Medicine, Naples, Italy
Cancer Invest 28:820-7. 2010
..The EUS maximal transverse cross sectional area reduction >50% significantly correlated with pathCR. Three-year survival rate was 35%. These results support the activity and mild toxicity of this regimen...
Antitumor activity of sorafenib in human cancer cell lines with acquired resistance to EGFR and VEGFR tyrosine kinase inhibitorsFloriana Morgillo
Division of Medical Oncology, Department of Clinical and Experimental Medicine and Surgery F Magrassi e A Lanzara Second University of Naples, Naples, Italy
PLoS ONE 6:e28841. 2011
..These data suggest that resistance to EGFR inhibitors is predominantly driven by the RAS/RAF/MAPK pathway and can be overcame by treatment with sorafenib...
- Antitumor activity of bortezomib in human cancer cells with acquired resistance to anti-epidermal growth factor receptor tyrosine kinase inhibitors
Floriana Morgillo
Oncologia Medica, Dipartimento Medico Chirurgico di Internistica Clinica e Sperimentale F Magrassi e A Lanzara, Seconda Universita degli Studi di Napoli, Via S Pansini 5, 80131 Naples, Italy
Lung Cancer 71:283-90. 2011
..These results suggest that bortezomib treatment could be a useful approach to overcome resistance to anti-EGFR therapies...
- TLR9 agonist acts by different mechanisms synergizing with bevacizumab in sensitive and cetuximab-resistant colon cancer xenografts
Vincenzo Damiano
Departments of Endocrinologia e Oncologia Molecolare e Clinica, Universita di Napoli Federico II, 80131 Napoli, Italy
Proc Natl Acad Sci U S A 104:12468-73. 2007
....
- Sequence-dependent, synergistic antiproliferative and proapoptotic effects of the combination of cytotoxic drugs and enzastaurin, a protein kinase Cbeta inhibitor, in non-small cell lung cancer cells
Floriana Morgillo
Dipartimento Medico Chirurgico di Internistica Clinica e Sperimentale, F Magrassi e A Lanzara, Seconda Universita degli Studi di Napoli, Via S Pansini 5, 80131 Naples, Italy
Mol Cancer Ther 7:1698-707. 2008
..In contrast, the concomitant treatments or the sequential treatments, in which enzastaurin was given before chemotherapy, resulted in significant antagonistic effects...
- Antiangiogenic drugs in non-small cell lung cancer treatment
Tina Cascone
Cattedra di Oncologia Medica, Dipartimento Medico-Chirurgico di Internistica Clinica e Sperimentale F Magrassi e A Lanzara, , Naples, Italy
Curr Opin Oncol 18:151-5. 2006
..The combination of bevacizumab and conventional chemotherapy could offer a new therapeutic option in selected non-small cell lung cancer histotypes...
- Synergistic anti-proliferative and pro-apoptotic activity of combined therapy with bortezomib, a proteasome inhibitor, with anti-epidermal growth factor receptor (EGFR) drugs in human cancer cells
Tina Cascone
Division of Medical Oncology, Department of Clinical and Experimental Medicine and Surgery F Magrassi and A Lanzara, Second University of Naples, Naples, Italy
J Cell Physiol 216:698-707. 2008
....
- ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases
Francesca Carlomagno
Istituto di Endocrinologia ed Oncologia Sperimentale del Consiglio Nazionale delle Ricerche, Dipartimento di Biologia e Patologia Cellulare e Molecolare Luigi Califano, University Federico II, Naples, Italy
Cancer Res 62:7284-90. 2002
..Thus, targeting RET oncogenes with ZD6474 might offer a potential treatment strategy for carcinomas sustaining oncogenic activation of RET...
- Adjuvant chemoradiotherapy in patients with stage III or IV radically resected gastric cancer: a pilot study
Michele Orditura
Division of Medical Oncology, F Magrassi A Lanzara Department of Clinical and Experimental Medicine and Surgery, Second University of Naples School of Medicine, c o II Policlinico, Via Pansini 5, Naples, Italy
Arch Surg 145:233-8. 2010
..We assessed the feasibility and toxic effects of chemoradiotherapy as adjuvant treatment in locally advanced gastric cancer...
- Implications of KRAS mutation status for the treatment of metastatic colorectal cancer
Fortunato Ciardiello
Division of Medical Oncology, Department of Experimental and Clinical Medicine and Surgery F Magrassi and A Lanzara, Second University of Naples, Naples, Italy
Target Oncol 4:311-22. 2009
..In view of this, testing for tumor KRAS mutation status should be mandatory at diagnosis of mCRC, prior to treatment decision-making...
- Determination of molecular marker expression can predict clinical outcome in colon carcinomas
Gennaro Galizia
Division of Surgical Oncology, Second University of Naples School of Medicine, Naples, Italy
Clin Cancer Res 10:3490-9. 2004
..involved in cell cycle regulation (p27 and p53), apoptosis (p53 and p27), and tumor neoangiogenesis [p53, vascular endothelial growth factor (VEGF), and microvessel count] in predicting tumor behavior and clinical outcome in CRC patients..
- Combined targeted therapies in non-small cell lung cancer: a winner strategy?
Tina Cascone
Dipartimento Medico Chirurgico di Internistica Clinica e Sperimentale F Magrassi e A Lanzara, Seconda Universita degli Studi di Napoli, Naples, Italy
Curr Opin Oncol 19:98-102. 2007
..The complexity of the signalling process leading to cancer cell proliferation and to the neoplastic phenotype supports the necessity of interfering at different stages to avoid cancer cell resistance to therapy...
- Combination of standard chemotherapy and targeted agents
Maria Anna Bareschino
Dipartimento Medico-Chirurgico di Internistica Clinica e Sperimentale F. Magrassi e A. Lanzara, , Naples, Italy
J Thorac Oncol 2:S19-23. 2007
- Correlation between efficacy and skin rash occurrence following treatment with the epidermal growth factor receptor inhibitor cetuximab: a single institution retrospective analysis
Michele Orditura
Division of Medical Oncology, F Magrassi A Lanzara Department of Clinical and Experimental Medicine, Second University of Naples School of Medicine, c o II Policlinico, 80131 Naples, Italy
Oncol Rep 21:1023-8. 2009
..Skin toxicity was confirmed as the only clinical variable able to predict the response to cetuximab...
- The use of xenograft models for the selection of cancer treatments with the EGFR as an example
Teresa Troiani
Dipartimento Medico Chirurgico di Internistica Clinica e Sperimentale F Magrassi e A Lanzara, Seconda Universita degli Studi di Napoli, Naples, Italy
Crit Rev Oncol Hematol 65:200-11. 2008
..Here we review the value and the limitations of xenograft models and their role in developing new anti-cancer treatments...
- Combined targeting of EGFR-dependent and VEGF-dependent pathways: rationale, preclinical studies and clinical applications
Giampaolo Tortora
Clinical Unit and Laboratories of Molecular Therapy at the University of Naples Federico II, Naples, Italy
Nat Clin Pract Oncol 5:521-30. 2008
..This Review discusses the experimental rationale for, preclinical studies of and clinical trials on combined blockade of ERBB and VEGF signaling...
- Perspectives in adjuvant therapy of gastric cancer
Ferdinando De Vita
Medical Oncology, Department of Clinical and Experimental Medicine F Magrassi and A Lanzara, Second University of Naples, Naples, Italy
Oncology 77:38-42. 2009
..Therefore, at present the routine use of adjuvant therapy should be regarded as an investigational approach. Improved clinical trial designs with standardized surgical techniques and the incorporation of newer active drugs are needed...
- Hepatoid carcinoma colliding with a liposarcoma of the left colon serosa presenting as an abdominal mass
Michele Orditura
Cattedra di Oncologia Medica, Seconda Università degli Studi di Napoli Ospedale Da Procida, Salerno, Naples, Italy
World J Surg Oncol 5:42. 2007
..Stomach is the most frequent site where hepatoid adenocarcinoma occurs, although it has been described in many other organs. On the other side, liposarcoma is a rare, malignant tumor that develops from fat cells...
- The role of EGFR inhibitors in nonsmall cell lung cancer
Fortunato Ciardiello
Cattedra di Oncologia Medica, Dipartimento Medico Chirurgico di Internistica Clinica e Sperimentale F Magrassi e A Lanzara, Seconda Universita degli Studi di Napoli, Naples, Italy
Curr Opin Oncol 16:130-5. 2004
..Several antiepidermal growth factor receptor agents are in clinical development. This review focuses on the available clinical data on epidermal growth factor receptor-targeting drugs in the treatment of nonsmall cell lung cancer...
- External beam radiotherapy in bone metastatic prostate cancer: impact on patients' pain relief and quality of life
Giuseppe Di Lorenzo
Cattedra di Oncologia Medica, Dipartimento di Endocrinologia e Oncologia Molecolare e Clinica, , Napoli, Italy
Oncol Rep 10:399-404. 2003
..Minimal side effects were experienced and QoL improved as shown by the results of the specific questionnaire...
- Epidermal growth factor receptor tyrosine kinase inhibitors in late stage clinical trials
Fortunato Ciardiello
Cattedra di Oncologia Medica, Dipartimento Medico Chirurgico di Internistica Clinica e Sperimentale F Magrassi e A Lanzara, Seconda Universita degli Studi di Napoli, Via S Pansini 5, 80131 Napoli, Italy
Expert Opin Emerg Drugs 8:501-14. 2003
..Furthermore, continuing clinical trials and a series of open clinical issues for the development of optimal strategies of using EGFR-targeting agents will be discussed...
- Pegylated liposomal doxorubicin: pharmacologic and clinical evidence of potent antitumor activity with reduced anthracycline-induced cardiotoxicity (review)
Michele Orditura
Division of Medical Oncology, F. Magrassi-A. Lanzara Department of Clinical and Experimental Medicine and Surgery, Second University of Naples School of Medicine, Via S. Pansini 5, 80131 Naples, Italy
Oncol Rep 12:549-56. 2004
..Here, we review the pharmacologic properties of PLD as well as the results of phases I, II and III trials demonstrating activity and low cardiac toxicity associated with the use of this novel drug...
- Implications for KRAS status and EGFR-targeted therapies in metastatic CRC
Nicola Normanno
Cell Biology and Biotherapy Unit, INT Fondazione Pascale, Naples, Italy
Nat Rev Clin Oncol 6:519-27. 2009
..We summarize the experimental and clinical evidence supporting the use of KRAS testing for the optimal selection of patients with mCRC to be treated with anti-EGFR monoclonal antibodies...
- Rational bases for the development of EGFR inhibitors for cancer treatment
Roberto Bianco
Dipartimento di Endocrinologia e Oncologia Molecolare e Clinica, Universita di Napoli Federico II, Via S Pansini 5, 80131 Naples, Italy
Int J Biochem Cell Biol 39:1416-31. 2007
..This article reviews the EGFR role in carcinogenesis and tumor progression as rational bases for the development of specific therapeutic inhibitors...
- Overcoming resistance to molecularly targeted anticancer therapies: Rational drug combinations based on EGFR and MAPK inhibition for solid tumours and haematologic malignancies
Giampaolo Tortora
Dipartimento di Endocrinologia e Oncologia Molecolare e Clinica, Universita di Napoli Federico II, Naples, Italy
Drug Resist Updat 10:81-100. 2007
....
- Primary and acquired resistance to anti-EGFR targeted drugs in cancer therapy
Floriana Morgillo
Dipartimento Medico Chirurgico di Internistica Clinica e Sperimentale F Magrassi e A Lanzara, Seconda Universita degli Studi di Napoli, Via Pansini 5 80131 Napoli, Italy
Differentiation 75:788-99. 2007
..This review will focus on the most relevant mechanisms contributing to the acquisition of sensitivity/resistance to EGFR inhibitors...
- Beyond bevacizumab: new anti-VEGF strategies in colorectal cancer
Teresa Troiani
Oncologia Medica, Dipartimento Medico Chirurgico di Internistica Clinica e Sperimentale F Magrassi e A Lanzara, Seconda Universita degli Studi di Napoli, Via S Pansini 5, 80131 Napoli, Italia
Expert Opin Investig Drugs 21:949-59. 2012
....
- p27 downregulation and metallothionein overexpression in gastric cancer patients are associated with a poor survival rate
Gennaro Galizia
Division of Surgical Oncology, F Magrassi A Lanzara Department of Clinical and Experimental Medicine and Surgery, Second University of Naples School of Medicine, Naples, Italy
J Surg Oncol 93:241-52. 2006
....
- Chemosensitization by antisense oligonucleotides targeting MDM2
Roberto Bianco
Dipartimento di Endocrinologia e Oncologia Molecolare e Clinica, , Via S. Pansini 5, 80131 Naples, Italy
Curr Cancer Drug Targets 5:51-6. 2005
....
- In vitro expansion of human breast cancer epithelial and mesenchymal stromal cells: optimization of a coculture model for personalized therapy approaches
Bianca Maria Veneziani
Dipartimento di Biologia e Patologia Cellulare e Molecolare L Califano, Universita di Napoli Federico II, Via S Pansini 5, 80131 Naples, Italy
Mol Cancer Ther 6:3091-100. 2007
....
- Key cancer cell signal transduction pathways as therapeutic targets
Roberto Bianco
Dipartimento di Endocrinologia e Oncologia Molecolare e Clinica, , Via S. Pansini 5, 80131 Napoli, Italy
Eur J Cancer 42:290-4. 2006
....
- Intrinsic and acquired resistance to EGFR inhibitors in human cancer therapy
Roberto Bianco
Dipartimento di Endocrinologia Molecolare e Clinica, , Naples, Italy
Endocr Relat Cancer 12:S159-71. 2005
..However, the intrinsic molecular mechanisms of resistance to these drugs are still unclear. This review will focus on the preclinical findings on therapeutic resistance to EGFR targeting agents...
- Cetuximab in the treatment of colorectal cancer
Fortunato Ciardiello
Seconda Universita degli Studi di Napoli, Cattedra di Oncologia Medica, Dipartimento Medico Chirurgico di Internistica Clinica Sperimentale F Magrassi e A Lanzara, Via S Pansini 5, 80131 Napoli, Italy
Future Oncol 1:173-81. 2005
....
- EGFR antagonists in cancer treatment
Fortunato Ciardiello
Division of Medical Oncology, Department of Experimental and Clinical Medicine and Surgery F. Magrassi and A. Lanzara, Second University of Naples, Naples, Italy
N Engl J Med 358:1160-74. 2008
- EGFR-targeted therapy
Loredana Vecchione
Digestive Oncology Unit, University Hospital Gasthuisberg, Herestraat 49 bus 602 Be 3000, Leuven, Belgium
Exp Cell Res 317:2765-71. 2011
....
- Antisense strategies targeting protein kinase C: preclinical and clinical development
Giampaolo Tortora
Department of Molecular and Clinical Endocrinology and Oncology, , Naples, Italy
Semin Oncol 30:26-31. 2003
..Studies in other tumor types will also investigate the benefit of combining LY900003 with conventional chemotherapy...
- Protein kinase A as target for novel integrated strategies of cancer therapy
Giampaolo Tortora
Cattedra di Oncologia Medica, Dipartimento di Endocrinologia e Oncologia Molecolare e Clinica, Universita di Napoli Federico II, 80131 Napoli, Italy
Ann N Y Acad Sci 968:139-47. 2002
..Finally, we have shown that AS-PKA-I also has antitumor and antiangiogenic effects following oral administration and that they can be greatly enhanced in combination with oral ZD1839 and oral taxanes...
- Angiogenesis: a target for cancer therapy
Giampaolo Tortora
Division of Medical Oncology, Department of Molecular and Clinical Endocrinology and Oncology, Universita di Napoli Federico II, Via S Pansini 5, 80131 Naples, Italy
Curr Pharm Des 10:11-26. 2004
..In this review will be discussed the signal transduction mechanisms of angiogenic molecules, the development of specific inhibitors and their translation into clinical studies and, finally, the new perspectives in antiangiogenic therapy...
- [EGF receptor blockade with monoclonal antibodis and so-called "small molecules"]
Fortunato Ciardiello
Division of Medical Oncology, Department of Clinical and Experimental Medicine, Seconda Universita di Napoli, Naples, Italy
Onkologie 28:18-24. 2005
- Elevated perioperative serum vascular endothelial growth factor levels in patients with colon carcinoma
Ferdinando De Vita
Division of Medical Oncology, F Magrassi A Lanzara Department of Clinical and Experimental Medicine, Second University of Naples School of Medicine, II Policlinico, Via S Pansini 5, 90131 Naples, Italy
Cancer 100:270-8. 2004
....
- Antisense targeting protein kinase A type I as a drug for integrated strategies of cancer therapy
Giampaolo Tortora
Division of Medical Oncology, Department of Molecular and Clinical Endocrinology and Oncology, Universita di Napoli Federico II, 80131 Napoli, Italy
Ann N Y Acad Sci 1002:236-43. 2003
..These studies support the development of AS-PKAI as a novel anticancer agent and suggest its potentially relevant role when integrated with conventional treatments and/or other signaling inhibitors in novel therapeutic strategies...
- Involvement of growth factor receptors of the epidermal growth factor receptor family in prostate cancer development and progression to androgen independence
Giuseppe Di Lorenzo
Department of Molecular and Clinical Endocrinology, Universita degli Studi di Napoli Federico II, Naples, Italy
Clin Prostate Cancer 2:50-7. 2003
....
- Detection of erbB2 copy number variations in plasma of patients with esophageal carcinoma
Immacolata Andolfo
CEINGE, Centro di Ingegneria Genetica e Biotecnologia Avanzate, Naples, Italy
BMC Cancer 11:126. 2011
..Here, we sought to isolate cell-free DNA released into the plasma of patients with esophageal carcinoma, to analyze copy number variations of marker genes in the search for early detection of tumor progression...
- CRIPTO-1: a novel target for therapeutic intervention in human carcinoma
Nicola Normanno
Department of Experimental Oncology, INT Fondazione Pascale, Via Mariano Semmola, I 80131 Naples, Italy
Int J Oncol 25:1013-20. 2004
..Taken together, these data strongly suggest that CR-1 might represent a novel target for therapeutic intervention in different carcinoma types...
- Epidermal growth factor receptor inhibitors in cancer treatment
Fortunato Ciardiello
Cattedra di Oncologia Medica, Dipartimento Medico Chirurgico di Internistica Clinica e Sperimentale F Magrassi e A Lanzara, Seconda Universita degli Studi di Napoli, Via S Pansini 5, 80131 Napoli, Italy
Future Oncol 1:221-34. 2005
..Furthermore, a series of open clinical issues for the development of optimal strategies of using EGFR-targeting agents will be discussed...
- Trying to compose the puzzle with all the pieces: epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer
Massimo Di Maio
Clinical Trials Unit, National Cancer Institute of Naples, Naples, Italy
J Cell Physiol 205:355-63. 2005
....
- The rational basis of using novel targeted biological agents in non-small cell lung cancer
Fortunato Ciardiello
Cattedra di Oncologia Medica, Dipartimento di Endocrinologia e Oncologia Molecolare e Clinica, , Naples, Italy
Suppl Tumori 1:S31-3. 2002
- Chronic inflammation and oxidative stress in human carcinogenesis
Alessandro Federico
Division of Gastroenterology, F Magrassi and A Lanzara Medical Surgical Department, Second University of Naples, Naples, Italy
Int J Cancer 121:2381-6. 2007
..This review focalizes some of these intricate events by discussing the relationships occurring among oxidative/nitrosative/metabolic stress, inflammation and cancer...
- Novel investigational drugs for gastric cancer
Loredana Vecchione
Second University of Naples, School of Medicine, Division of Medical Oncology F Magrassi and A Lanzara, Department of Clinical and Experimental Medicine and Surgery, c o II Policlinico Via S Pansini 5, 80131 Naples, Italy
Expert Opin Investig Drugs 18:945-55. 2009
..Several cytotoxic agents have demonstrated activity and combination regimens improve progression-free survival, overall survival and quality of life. Nevertheless, now there is no standard therapy for advanced gastric cancer patients...
- Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer
Giuseppe Di Lorenzo
Cattedra di Oncologia Medica, Dipartimento di Endocrinologia e Oncologia Molecolare e Clinica, Universita degli Studi di Napoli Federico II, 80131 Naples, Italy
Clin Cancer Res 8:3438-44. 2002
..We investigated EGFR and c-erbB-2 expression in primary androgen-dependent and in advanced androgen-independent prostate cancer and their potential role as markers of disease progression...
- Interference with EGFR signaling: paradigm for improving radiation response in cancer treatment
David Raben
University of Colorado Health Sciences Center, Anschutz Cancer Pavilion, Department of Radiation Oncology, Aurora 80010 0510, USA
Expert Rev Anticancer Ther 2:461-71. 2002
..Thus, emerging rapidly are cancer treatment strategies based on an improved understanding of the specific cellular and molecular abnormalities of individual tumors...
- Antitumor activity of ZD6126, a novel vascular-targeting agent, is enhanced when combined with ZD1839, an epidermal growth factor receptor tyrosine kinase inhibitor, and potentiates the effects of radiation in a human non-small cell lung cancer xenograft
David Raben
Department of Radiation Oncology, University of Colorado Health Sciences Center, Anschutz Cancer Pavilion, 1665 North Ursula Street, Suite 1032, Box F706, Aurora, CO 80010 0510, USA
Mol Cancer Ther 3:977-83. 2004
....
- Understanding the mechanisms of action of EGFR inhibitors in NSCLC: what we know and what we do not know
David Raben
University of Colorado Cancer Center, Department of Radiation Oncology, University of Colorado Health Sciences Center, Denver, CO 80010 5010, USA
Lung Cancer 41:S15-22. 2003
....
- Potential role of molecularly targeted therapy in the management of advanced nonsmall cell lung carcinoma in the elderly
Cesare Gridelli
Division of Medical Oncology, San Giuseppe Moscati Hospital, Avellino, Italy
Cancer 101:1733-44. 2004
..For such elderly patients, alternatives to conventional chemotherapy, such as novel molecularly targeted therapy regimens, are of interest...
- Role of the cripto (EGF-CFC) family in embryogenesis and cancer
Caterina Bianco
Tumor Growth Factor Section, Mammary Biology and Tumorigenesis Laboratory, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
Growth Factors 22:133-9. 2004
- ZD1839 (Iressa): preclinical studies and pharmacology
Fortunato Ciardiello
Dipartimento di Endcorinologia e Oncologia Molecolare e Clinica, , , Naples
Tumori 88:S155-7. 2002
- Implication of the insulin-like growth factor-IR pathway in the resistance of non-small cell lung cancer cells to treatment with gefitinib
Floriana Morgillo
Department of Thoracic Head and Neck Medical Oncology, M D Anderson Cancer Center, Houston, TX 77030, USA
Clin Cancer Res 13:2795-803. 2007
..In this study, we determined whether the insulin-like growth factor I (IGF-I) signaling pathway induces resistance of non-small cell lung cancer (NSCLC) cells to the EGFR tyrosine kinase inhibitor gefitinib...
- Epidermal growth factor receptor (EGFR) inhibitors in cancer therapy
Fortunato Ciardiello
Division of Medical Oncology, Department of Experimental and Clinical Medicine and Surgery, F Magrassi and A Lanzara, Second University of Naples, Via S. Pansini 5, 80131 Napoli, Italy
Prog Drug Res 63:93-114. 2005
- The effects of cetuximab alone and in combination with radiation and/or chemotherapy in lung cancer
David Raben
Tobacco Related Malignancy Program, Department of Radiation Oncology, Anschutz Cancer Pavilion, University of Colorado Health Sciences Center, 1165 North Ursula Street F706, Aurora, CO 80010 0510, USA
Clin Cancer Res 11:795-805. 2005
..In this report, we investigated the cellular and molecular effects of cetuximab alone and in combination with radiation and/or chemotherapy in human NSCLC cell lines with varying levels of EGFR overexpression in vitro and in vivo...
- Prospective study of gefitinib in epidermal growth factor receptor fluorescence in situ hybridization-positive/phospho-Akt-positive or never smoker patients with advanced non-small-cell lung cancer: the ONCOBELL trial
Federico Cappuzzo
Department of Hematology Oncology, Istituto Clinico Humanitas IRCCS, Rozzano, Italy
J Clin Oncol 25:2248-55. 2007
..The ONCOBELL trial is a prospective phase II study evaluating gefitinib sensitivity in NSCLC patients who never smoked or have increased EGFR gene copy number or activation of the antiapoptotic protein Akt...
- A randomized phase II study of sorafenib/gemcitabine or sorafenib/erlotinib for advanced non-small-cell lung cancer in elderly patients or patients with a performance status of 2: treatment rationale and protocol dynamics
Cesare Gridelli
Division of Medical Oncology, S G Moscati Hospital, Avellino, Italy
Clin Lung Cancer 8:396-8. 2007
..The study will enroll 100 patients: 58 patients aged >or= 70 years with a PS of 0-2 and 42 patients aged < 70 years with a PS of 2. The analysis will be conducted differently for the 2 groups of patients...
- Synergistic antitumor activity of ZD6474, an inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling, with gemcitabine and ionizing radiation against pancreatic cancer
Cataldo Bianco
Division of Radiotherapy, Department of Oncology, Transplants and Advanced Technologies in Medicine, University of Pisa, Pisa, Italy
Clin Cancer Res 12:7099-107. 2006
..These findings support the investigation of this combination in the clinical setting...
- Sequence-dependent inhibition of human colon cancer cell growth and of prosurvival pathways by oxaliplatin in combination with ZD6474 (Zactima), an inhibitor of VEGFR and EGFR tyrosine kinases
Teresa Troiani
University of Colorado Cancer Center, 12801 East 17th Avenue, Aurora, CO 80010, USA
Mol Cancer Ther 5:1883-94. 2006
..ZD6474 in combination with oxaliplatin has synergistic antiproliferative properties in human colorectal cancer cell lines in vitro when oxaliplatin is administered before ZD6474...
- Anti-tumor activity of the combination of cetuximab, an anti-EGFR blocking monoclonal antibody and ZD6474, an inhibitor of VEGFR and EGFR tyrosine kinases
Maria Pia Morelli
Dipartimento Medico-Chirurgico di Internistica Clinica e Sperimentale F. Magrassi e A. Lanzara, , Napoli, Italy
J Cell Physiol 208:344-53. 2006
..CONCLUSIONS: This study provides a rationale for evaluating in a clinical setting the double blockade of EGFR in combination with inhibition of VEGFR-2 signaling as cancer therapy...
- Erlotinib in non-small cell lung cancer treatment: current status and future development
Cesare Gridelli
Division of Medical Oncology, SG Moscati Hospital, Città Ospedaliera, Contrada Amoretta, Avellino, Italy
Oncologist 12:840-9. 2007
....
- Investigation of two dosing schedules of vandetanib (ZD6474), an inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling, in combination with irinotecan in a human colon cancer xenograft model
Teresa Troiani
Division of Medical Oncology, University of Colorado at Denver and Health Sciences Center, Aurora, Colorado, USA
Clin Cancer Res 13:6450-8. 2007
....
- Rational combination of targeted therapies as a strategy to overcome the mechanisms of resistance to inhibitors of EGFR signaling
Roberto Bianco
Dipartimento Medico Chirurgico di Internistica Clinica e Sperimentale, Seconda Universita di Napoli, Napoli, Italy
Curr Pharm Des 13:3358-67. 2007
..This review focuses on the role of complementary signalling pathways in the development of resistance to EGFR targeting agents and the rationale to combine novel inhibitors as anticancer therapy...
- Combining targeted therapies and drugs with multiple targets in the treatment of NSCLC
Paolo Maione
Division of Medical Oncology, S G Moscati Hospital, Contrada Amoretta, 83100 Avellino, Italy
Oncologist 11:274-84. 2006
..Whether the multitargeted approach is best performed using combinations of selective agents or agents that intrinsically target various targets is a matter of debate...
- ZD6474, an inhibitor of VEGFR and EGFR tyrosine kinase activity in combination with radiotherapy
Barbara Frederick
Department of Radiation Oncology, University of Colorado Health Sciences Center, Aurora, CO 80010-0510, USA
Int J Radiat Oncol Biol Phys 64:33-7. 2006
..We also discuss ZD6474 in the context of anti-EGFR therapy resistance. Dual inhibition of EGFR and VEGF receptor signaling pathways shows promise in enhancing RT efficacy...
- Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer
Josep Tabernero
Medical Oncology Department, Vall d Hebron University Hospital, P Vall d Hebron, 119 129, 08035 Barcelona, Spain
J Clin Oncol 25:5225-32. 2007
....
- Second-line treatment of advanced non-small cell lung cancer
Cesare Gridelli
Medical Oncology, S G Moscati Hospital, Avellino, Italy
J Thorac Oncol 3:430-40. 2008
..Further research is mandatory, to find better treatments, and to identify clinical and molecular predictive markers of efficacy, both for chemotherapy and for novel biologic agents...
